2/25
07:00 am
upb
Upstream Bio to Participate in Upcoming March Investor Conferences
Medium
Report
Upstream Bio to Participate in Upcoming March Investor Conferences
2/12
02:02 pm
upb
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data [Seeking Alpha]
Low
Report
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data [Seeking Alpha]
2/11
06:00 am
upb
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
High
Report
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
2/10
06:52 pm
upb
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma [Yahoo! Finance]
High
Report
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma [Yahoo! Finance]
2/10
06:00 pm
upb
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
High
Report
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
1/8
12:20 pm
upb
Upstream Bio: Fully Priced After Recent Rally [Seeking Alpha]
Low
Report
Upstream Bio: Fully Priced After Recent Rally [Seeking Alpha]
1/5
07:00 am
upb
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/19
05:59 am
upb
Upstream Bio (NASDAQ:UPB) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Medium
Report
Upstream Bio (NASDAQ:UPB) was upgraded by analysts at Mizuho to a "strong-buy" rating.
12/17
07:01 pm
upb
Upstream Bio (NASDAQ:UPB) was given a new $51.00 price target on by analysts at Mizuho.
Medium
Report
Upstream Bio (NASDAQ:UPB) was given a new $51.00 price target on by analysts at Mizuho.
12/5
04:51 pm
upb
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study [Seeking Alpha]
Medium
Report
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study [Seeking Alpha]
12/2
08:04 am
upb
Upstream Bio (NASDAQ:UPB) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $43.00 price target on the stock.
High
Report
Upstream Bio (NASDAQ:UPB) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $43.00 price target on the stock.